US-CONGRESS BILLS-119hr8205eh: Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends FDA expedited approval pathways and incentives for ALS therapies, with potential impacts on cGMP compliance, drug shortage reporting, and DEA quota adjustments for controlled substances used in ALS treatments.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 24, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities involved in ALS therapies or controlled substances should confirm how it applies to their specific situation before acting. There is a time constraint attached: Upon enactment (likely 2026); immediate review recommended to align with FDA guidance updates.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Reauthorization of accelerated approval and priority review vouchers for ALS therapies; may affect FDA inspection priorities, drug shortage lists, and DEA quota allocations for ALS-related controlled substances.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities involved in ALS therapies or controlled substances
What you must do
Review current ALS therapy pipeline and assess eligibility for expedited pathways; update cGMP documentation and shortage reporting procedures; monitor DEA quota adjustments for relevant controlled substances.
Deadline
Upon enactment (likely 2026); immediate review recommended to align with FDA guidance updates.
Source: https://www.govinfo.gov/app/details/BILLS-119hr8205eh
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- US-CONGRESS S5043: Secure Drug Supply Chain Act of 2026
- FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugs - JD Supra
- Order: Francis Esteban Matos: Final Debarment
- FDA revises compliance guide on pre-approval inspections - RAPS
- FDA Issues Guidance on Alternative Tools for Assessing Drug Manufacturing Facilities in Pending Applications - ArentFox Schiff